Alnylam Pharma (NASDAQ: ALNY) reported Q1 EPS of ($1.49), $0.35 better than the analyst estimate of ($1.84). Revenue for the quarter came in at $213.26 million versus the consensus estimate of $243.02 million.

For earnings history and earnings-related data on Alnylam Pharma (ALNY) click here.